NYGC Researchers Awarded Two-Year Target ALS Grant

Credit: Shutterstock

NEW YORK, NY (August 18, 2023) — Researchers at the New York Genome Center (NYGC) are collaborating under a recent grant from Target ALS, a medical research foundation committed to the search for effective treatments for Amyotrophic Lateral Sclerosis (ALS).

Hemali Phatnani, PhD, Core Faculty Member and Director of the Center for Genomics of Neurodegenerative Disease (CGND) and Sanja Vicković, PhD, Core Faculty Member and Director of the Technology Innovation Lab, have been awarded a two-year grant for their project titled “Creating a spatial genomics resource for Amyotrophic Lateral Sclerosis-Frontotemporal Dementia (ALS-FTD) neuropathies.”

This project will address the molecular mechanisms driving diverse ALS-FTD etiologies by applying spatially resolved genomics to deeply phenotyped, genetically stratified cortical and spinal tissue at an unprecedented scale, and engaging novel computational methods for data integration across experimental modalities.